Questions and Answers

How can I join the program «Supported Patient»?

Use the contact information on our site - give us a call or email us and we will keep you informed about upcoming events within the Program and invite you to participate. Also, if you require specialist advice - leave your contacts, we will contact you within one day, consult remotely, or invite you to our information center. 

Learn more

 

My mother had breast cancer, more than 5 years after surgery and chemotherapy. There are no recurrences of tumor and metastases. In this case, is it necessary to carry out anti-recurrent immunocorrection?

There is no doubt that in recent years, oncologists have been able to achieve good treatment outcomes in the vast majority of patients. But it is important to keep in mind that circulating tumor cells remain in the body after surgery and even after chemotherapy. By taking advantage of the woman's immunity being weakened, the cancer cells remain at risk of relapse and metastasis. Scientists have found that such dangerous cells can be detected in the blood of patients even 10 or more years after the main course of therapy [1-3]. Carrying out anti-relapse immuno-correction is aimed at setting immune cells to actively work against the hidden danger. It is also important that anti-relapse immunocorrection is a complex of therapeutic and prophylactic techniques aimed at improving the efficiency of immune cells without depleting the immune system's reserves.

Learn more

 

   I completed a course of antibiotics after exacerbation of chronic prostatitis. But I feel that not everything is normal, although the analysis show that  infection is not detected. What can be done?

Pain and uncomfortable sensations in the prostate can occur without infectious causes. Andrologists call this phenomenon chronic abacterial prostatitis. The disease is characterized by chronic inflammation, accompanied by unpleasant symptoms. It is important not to self-medicate, but to consult a specialist. After taking antibiotics to prevent recurrence of chronic prostatitis, it is advisable to carry out anti-relapse immunocorrection.

Learn more 

 

I have completely undergone 6 courses of chemotherapy after bowel tumor removal. To reduce the harmful effects of chemistry took hepatoprotectors, probiotics, omega-3s, vitamins. And yet I'm not feeling well. I want almost nothing, and if I stuff myself with food, I either get nauseous or my diarrhea begins. How can this be handled?

Practice confirms that even effective chemotherapy drugs suppress the immune system and also have toxic effects on various organs. First of all, the remnants of the tumor cells destroyed by treatment should be removed from the gastrointestinal tract – experts recommend a natural and safe pectin-containing complex «Gastroclin» for this purpose. Gastrocline helps to normalize the work of bowel, prevents congestion and prevents inflammation. Also, along with the recovery of the digestive system, immunity should be maintained - a method for anti-recurrent immunocorrection has been developed.

Learn more about Gastrocline

Anti-recurrent immunocorrection

 

From cystitis I was prescribed phosphomycin. There are many tips on the Internet that after cystitis you should take some herbal remedies, tinctures of herbs for recovery. Is it possible to drink «Essiac» tea for this purpose?

Yes, you can. Phytotherapy collection «Essiak» is effective for infectious-inflammatory diseases, in particular for cystitis. Essiac contains anthraquinones, which have pronounced anti-inflammatory and antibacterial properties.

Learn more about Essiac

  1. Pachmann K, Schuster S. The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients. Cancers (Basel). 2018;10(11):407.

  2. Meng S.,Tripathy D et al., Circulating Tumor Cells in Patients with Breast Cancer Dormancy. Clin Cancer Res December 15 2004 (10) (24) 8152-8162.

  3. Bankó, P., Lee, S.Y., Nagygyörgy, V. et al. Technologies for circulating tumor cell separation from whole blood. J Hematol Oncol 12, 48 (2019).

Ask a question

Send a question